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Objectives: The objective of this work was to describe the 5-year long term antifracture 
efficacy of strontium ranelate in TROPOS1 study. 
Methods: Strontium ranelate is a recent anti-osteoporotic treatment which efficacy is based 
on a new and unique mode of action both increasing bone formation and decreasing bone 
resorption. 
The TROPOS (TReatment Of Peripheral OSteoporosis) phase III study, performed in 75 
European and Australian centres, enrolled 5091 Caucasian women with postmenopausal 
osteoporosis with mean age (SD) of 76.7(5) years and with mean femoral neck BMD T-score 
(SD) of -3.1(0.6). The patients were randomly assigned to receive strontium ranelate 2g/day 
or placebo for 5 years as well as a supplementation with calcium and vitamin D according to 
their baseline status. The main statistical analysis was performed over 3 years of treatment 
and demonstrated efficacy of strontium ranelate at vertebral and non-vertebral sites including 
a significant decrease in hip fracture risk demonstrated in patients at risk over the same 
treatment period. 
Results: The 5-year results of TROPOS confirmed the long term vertebral and non-vertebral 
antifracture efficacy of strontium ranelate in the intent-to-treat population (n=2479 in 
strontium ranelate group and 2453 in placebo group) already shown over 3 years. The 
vertebral risk of fracture was significantly reduced by 24% (RR=0.76; 95% CI[0.65;0.87] Cox 
model: p<0.001). The non-vertebral fracture risk was decreased by 15% (RR=0.85; 95% 
CI[0.77;0.99] Cox model: p=0.03) In addition, the hip antifracture efficacy of strontium 
ranelate was assessed in women at particular high risk (age > 74 years with lumbar and 
femoral neck BMD T- score < -2.4 according to NHANES normative values). In these 
patients, (n= 1128, mean age (SD) 79.2(4.4), mean lumbar T-score= –4.2, mean femoral neck 
T-score= –3.0), strontium ranelate demonstrated a 43% reduction of the risk of hip fracture 
(RR=0.57; 95% CI[0.33;0.97] Cox model: p=0.036). 
Conclusion: These results confirm a sustained efficacy of strontium ranelate over five years 
against vertebral, non-vertebral and hip fractures. 
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